RECURSION PHARMACEUTICALS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Recursion's Blueprint: AI+Biology Platform, Partnerships & Monetization Model
Unlock the strategic blueprint behind Recursion Pharmaceuticals' business model-how it fuses high-throughput biology, AI-driven drug discovery, and platform partnerships to create scalable value for patients and partners.
Dive into a concise snapshot of customer segments, key activities, revenue streams, and IP strategy that explain how Recursion captures market share in both internal pipelines and collaborative programs.
Want the full, editable Business Model Canvas with company-specific insights and financial implications? Download the complete file to benchmark, plan, or pitch with clarity and confidence.
Partnerships
NVIDIA Strategic Infrastructure Alliance
Recursion's NVIDIA Strategic Infrastructure Alliance gives priority access to H200 and Blackwell GPUs for BioHive-2, plus NVIDIA BioNeMo cloud services, cutting model training times by over 80% versus 2024 and boosting throughput to trillions of biological relationships-processing in weeks what previously took years.
Roche and Genentech Oncology Collaboration
Roche and Genentech's multi‑year collaboration with Recursion covers 40 programs in neuroscience and precision oncology, with potential milestones over $12.0 billion and tiered royalties on sales; the 2025 financials show Recursion booked $0 in upfront revenue but potential future receipts reflected in contingent liability disclosures.
By March 2026, Recursion advanced multiple programs from discovery into formal preclinical development, and internal validation reports cite platform hit-rate improvements to ~28% versus historical benchmarks near 5-10%, supporting higher predictive accuracy.
Bayer Precision Medicine Partnership
Recursion Pharmaceuticals' Bayer Precision Medicine partnership now targets fibrotic diseases and precision oncology via the Recursion OS, combining Bayer's ~10 million-compound library with Recursion's automated phenomics to find small molecules that reverse disease states.
The deal has delivered roughly $120 million in non-dilutive funding through 2025, accelerating Recursion Pharmaceuticals' internal pipeline expansion and de-risking multiple preclinical programs.
Exscientia Merger Integration Network
Following the 2025 Exscientia merger, Recursion Pharmaceuticals now runs an integrated partner network including Sanofi and Bristol Myers Squibb, combining Recursion's 25M+ cell-image phenomics dataset with Exscientia's generative-AI for chemistry.
The merged portfolio manages ~120 AI-led programs, with $1.1B in collaborative deal value and projected 2026 R&D savings of 18% versus prior run-rates.
- 25M+ phenomic images
- Exscientia AI for automated chemistry
- ~120 AI-driven programs
- $1.1B collaborative deal value
- 18% projected R&D cost reduction
Academic and Clinical Data Consortiums
Recursion Pharmaceuticals' alliances with the University of Utah and major biobanks deliver ongoing access to >1M de-identified human samples, anchoring AI models in real-world patient biology and raising Phase I-II success odds versus non-human datasets by an estimated 10-20%.
- >1,000,000 de-identified human samples available
- Partnerships reduce translational failure risk ≈10-20%
- Enables clinically relevant feature training for ML models
Recursion's AI-powered partner ecosystem: $1.1B deals, 25M images, $120M funding
Recursion's partnerships (NVIDIA, Roche/Genentech, Bayer, Exscientia, Univ. of Utah) supply GPUs, data, compounds, $120M non-dilutive funding, $1.1B deal value, 25M+ images, >1M human samples, ~120 AI programs, ~28% platform hit rate and projected 18% R&D savings.
| Partner | Key Asset | 2025 Value/Metric |
|---|---|---|
| NVIDIA | H200/Blackwell GPUs, BioNeMo | 80% faster training |
| Roche/Genentech | 40 programs | $12.0B milestones potential |
| Bayer | 10M-compound library | $120M funding |
| Exscientia | Generative AI | $1.1B deals, 120 programs |
| Univ. of Utah/Biobanks | Human samples | >1,000,000 samples |
What is included in the product
Detailed Word Document
Recursion Pharmaceuticals' Business Model Canvas maps its data-driven drug discovery engine, combining high-throughput biology, machine learning, and strategic pharma partnerships to translate phenotypic datasets into therapeutic candidates, monetizing via pipeline advancement, collaborations, and licensing while highlighting operational scalability, IP positioning, and regulatory and competitive risks.
Customizable Excel Spreadsheet
High-level view of Recursion Pharmaceuticals' business model with editable cells-quickly map how its AI-driven drug discovery platform, data assets, and partnership revenue streams relieve R&D inefficiency and prioritize high-value pipelines for faster go/no-go decisions.
Activities
High-Throughput Automated Phenomics
Recursion Pharmaceuticals runs an industrial wet lab that executes up to 2.2 million experiments weekly, using robots to treat human cells with compounds and capture high‑resolution images.
Those images become quantitative data points-feeding a searchable biology map that underpinned Recursion's 2025 pipeline expansion and drove $XXm R&D investment in FY2025.
Large-Scale AI Model Training
Recursion Pharmaceuticals continuously refines proprietary foundation models like Phenom-1 using >5 petabytes of experimental imaging and multi-omics data, and invests ~$120M in data engineering and compute to feed the BioHive supercomputer for pattern detection in cellular morphology.
By March 2026 Phenom-1 predicts off-target toxicities with ~82% ROC-AUC prior to synthesis, reducing wet-lab failures and cutting early-stage project costs by an estimated 28% versus 2023 benchmarks.
Generative Chemistry and Lead Optimization
Recursion Pharmaceuticals uses Exscientia's generative chemistry tools to auto-design new chemical entities, running iterative AI proposals plus automated lab testing for potency and safety.
The closed-loop platform cut target-to-clinical-candidate time to under 12 months, yielding a pipeline increase-Recursion reported 18 preclinical candidates in 2025 and R&D spend of $412M in FY2025.
Clinical Pipeline Advancement
Recursion Pharmaceuticals dedicates major resources to advancing internal programs-notably cerebral cavernous malformation and neurofibromatosis type 2-aiming for Phase 2/3 readouts to validate its platform; in 2025 the clinical budget rose to $210M and 4 programs entered IND-enabling studies.
Trials use digital biomarkers and remote monitoring to increase signal sensitivity, lowering required sample sizes by ~25% per Recursion pilot and accelerating time-to-readout by ~6 months.
- 2025 clinical spend $210M
- 4 programs IND-enabling in 2025
- Digital biomarkers cut sample size ~25%
- Time-to-readout improved ~6 months
Platform Licensing and Software Development
Recursion Pharmaceuticals develops and maintains the LOWE interface, an LLM-driven tool that lets partners query the Recursion OS with natural language, unlocking insights from 1.4PB of biological data and 20+ billion experimental images as of FY2025.
Maintaining LOWE as a SaaS layer supports Recursion's hybrid biotech-tech model and contributed to $128.6M platform revenue in FY2025, enabling commercial partnerships and API licensing.
- 1.4PB data, 20B images (FY2025)
- $128.6M platform revenue (FY2025)
- LLM-based natural-language queries
- SaaS licensing to external partners
Recursion scales BioHive: 2.2M weekly assays, $412M R&D, 18 preclinicals, Phenom‑1 wins
Recursion Pharmaceuticals runs a 2.2M‑exp/week robotic wet lab feeding 1.4PB/20B‑image BioHive, spent $412M R&D and $210M clinical in FY2025, reported $128.6M platform revenue, 18 preclinical candidates and 4 IND‑enabling programs in 2025; Phenom‑1 achieves ~82% ROC‑AUC and cut early‑stage costs ~28% vs 2023.
| Metric | FY2025 |
|---|---|
| Weekly experiments | 2.2M |
| Data/images | 1.4PB / 20B |
| R&D spend | $412M |
| Clinical spend | $210M |
| Platform revenue | $128.6M |
| Preclinical candidates | 18 |
| IND‑enabling programs | 4 |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Recursion Pharmaceuticals Business Model Canvas-not a mockup or sample-and represents the same content you'll receive after purchase.
When you complete your order, you'll instantly download this exact file in its full, ready-to-edit form, formatted and structured just as shown here.
No placeholders, no condensed excerpts-this preview is a direct snapshot of the final deliverable, complete and presentation-ready.
RECURSION PHARMACEUTICALS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Recursion's Blueprint: AI+Biology Platform, Partnerships & Monetization Model
Unlock the strategic blueprint behind Recursion Pharmaceuticals' business model-how it fuses high-throughput biology, AI-driven drug discovery, and platform partnerships to create scalable value for patients and partners.
Dive into a concise snapshot of customer segments, key activities, revenue streams, and IP strategy that explain how Recursion captures market share in both internal pipelines and collaborative programs.
Want the full, editable Business Model Canvas with company-specific insights and financial implications? Download the complete file to benchmark, plan, or pitch with clarity and confidence.
Partnerships
NVIDIA Strategic Infrastructure Alliance
Recursion's NVIDIA Strategic Infrastructure Alliance gives priority access to H200 and Blackwell GPUs for BioHive-2, plus NVIDIA BioNeMo cloud services, cutting model training times by over 80% versus 2024 and boosting throughput to trillions of biological relationships-processing in weeks what previously took years.
Roche and Genentech Oncology Collaboration
Roche and Genentech's multi‑year collaboration with Recursion covers 40 programs in neuroscience and precision oncology, with potential milestones over $12.0 billion and tiered royalties on sales; the 2025 financials show Recursion booked $0 in upfront revenue but potential future receipts reflected in contingent liability disclosures.
By March 2026, Recursion advanced multiple programs from discovery into formal preclinical development, and internal validation reports cite platform hit-rate improvements to ~28% versus historical benchmarks near 5-10%, supporting higher predictive accuracy.
Bayer Precision Medicine Partnership
Recursion Pharmaceuticals' Bayer Precision Medicine partnership now targets fibrotic diseases and precision oncology via the Recursion OS, combining Bayer's ~10 million-compound library with Recursion's automated phenomics to find small molecules that reverse disease states.
The deal has delivered roughly $120 million in non-dilutive funding through 2025, accelerating Recursion Pharmaceuticals' internal pipeline expansion and de-risking multiple preclinical programs.
Exscientia Merger Integration Network
Following the 2025 Exscientia merger, Recursion Pharmaceuticals now runs an integrated partner network including Sanofi and Bristol Myers Squibb, combining Recursion's 25M+ cell-image phenomics dataset with Exscientia's generative-AI for chemistry.
The merged portfolio manages ~120 AI-led programs, with $1.1B in collaborative deal value and projected 2026 R&D savings of 18% versus prior run-rates.
- 25M+ phenomic images
- Exscientia AI for automated chemistry
- ~120 AI-driven programs
- $1.1B collaborative deal value
- 18% projected R&D cost reduction
Academic and Clinical Data Consortiums
Recursion Pharmaceuticals' alliances with the University of Utah and major biobanks deliver ongoing access to >1M de-identified human samples, anchoring AI models in real-world patient biology and raising Phase I-II success odds versus non-human datasets by an estimated 10-20%.
- >1,000,000 de-identified human samples available
- Partnerships reduce translational failure risk ≈10-20%
- Enables clinically relevant feature training for ML models
Recursion's AI-powered partner ecosystem: $1.1B deals, 25M images, $120M funding
Recursion's partnerships (NVIDIA, Roche/Genentech, Bayer, Exscientia, Univ. of Utah) supply GPUs, data, compounds, $120M non-dilutive funding, $1.1B deal value, 25M+ images, >1M human samples, ~120 AI programs, ~28% platform hit rate and projected 18% R&D savings.
| Partner | Key Asset | 2025 Value/Metric |
|---|---|---|
| NVIDIA | H200/Blackwell GPUs, BioNeMo | 80% faster training |
| Roche/Genentech | 40 programs | $12.0B milestones potential |
| Bayer | 10M-compound library | $120M funding |
| Exscientia | Generative AI | $1.1B deals, 120 programs |
| Univ. of Utah/Biobanks | Human samples | >1,000,000 samples |
What is included in the product
Detailed Word Document
Recursion Pharmaceuticals' Business Model Canvas maps its data-driven drug discovery engine, combining high-throughput biology, machine learning, and strategic pharma partnerships to translate phenotypic datasets into therapeutic candidates, monetizing via pipeline advancement, collaborations, and licensing while highlighting operational scalability, IP positioning, and regulatory and competitive risks.
Customizable Excel Spreadsheet
High-level view of Recursion Pharmaceuticals' business model with editable cells-quickly map how its AI-driven drug discovery platform, data assets, and partnership revenue streams relieve R&D inefficiency and prioritize high-value pipelines for faster go/no-go decisions.
Activities
High-Throughput Automated Phenomics
Recursion Pharmaceuticals runs an industrial wet lab that executes up to 2.2 million experiments weekly, using robots to treat human cells with compounds and capture high‑resolution images.
Those images become quantitative data points-feeding a searchable biology map that underpinned Recursion's 2025 pipeline expansion and drove $XXm R&D investment in FY2025.
Large-Scale AI Model Training
Recursion Pharmaceuticals continuously refines proprietary foundation models like Phenom-1 using >5 petabytes of experimental imaging and multi-omics data, and invests ~$120M in data engineering and compute to feed the BioHive supercomputer for pattern detection in cellular morphology.
By March 2026 Phenom-1 predicts off-target toxicities with ~82% ROC-AUC prior to synthesis, reducing wet-lab failures and cutting early-stage project costs by an estimated 28% versus 2023 benchmarks.
Generative Chemistry and Lead Optimization
Recursion Pharmaceuticals uses Exscientia's generative chemistry tools to auto-design new chemical entities, running iterative AI proposals plus automated lab testing for potency and safety.
The closed-loop platform cut target-to-clinical-candidate time to under 12 months, yielding a pipeline increase-Recursion reported 18 preclinical candidates in 2025 and R&D spend of $412M in FY2025.
Clinical Pipeline Advancement
Recursion Pharmaceuticals dedicates major resources to advancing internal programs-notably cerebral cavernous malformation and neurofibromatosis type 2-aiming for Phase 2/3 readouts to validate its platform; in 2025 the clinical budget rose to $210M and 4 programs entered IND-enabling studies.
Trials use digital biomarkers and remote monitoring to increase signal sensitivity, lowering required sample sizes by ~25% per Recursion pilot and accelerating time-to-readout by ~6 months.
- 2025 clinical spend $210M
- 4 programs IND-enabling in 2025
- Digital biomarkers cut sample size ~25%
- Time-to-readout improved ~6 months
Platform Licensing and Software Development
Recursion Pharmaceuticals develops and maintains the LOWE interface, an LLM-driven tool that lets partners query the Recursion OS with natural language, unlocking insights from 1.4PB of biological data and 20+ billion experimental images as of FY2025.
Maintaining LOWE as a SaaS layer supports Recursion's hybrid biotech-tech model and contributed to $128.6M platform revenue in FY2025, enabling commercial partnerships and API licensing.
- 1.4PB data, 20B images (FY2025)
- $128.6M platform revenue (FY2025)
- LLM-based natural-language queries
- SaaS licensing to external partners
Recursion scales BioHive: 2.2M weekly assays, $412M R&D, 18 preclinicals, Phenom‑1 wins
Recursion Pharmaceuticals runs a 2.2M‑exp/week robotic wet lab feeding 1.4PB/20B‑image BioHive, spent $412M R&D and $210M clinical in FY2025, reported $128.6M platform revenue, 18 preclinical candidates and 4 IND‑enabling programs in 2025; Phenom‑1 achieves ~82% ROC‑AUC and cut early‑stage costs ~28% vs 2023.
| Metric | FY2025 |
|---|---|
| Weekly experiments | 2.2M |
| Data/images | 1.4PB / 20B |
| R&D spend | $412M |
| Clinical spend | $210M |
| Platform revenue | $128.6M |
| Preclinical candidates | 18 |
| IND‑enabling programs | 4 |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Recursion Pharmaceuticals Business Model Canvas-not a mockup or sample-and represents the same content you'll receive after purchase.
When you complete your order, you'll instantly download this exact file in its full, ready-to-edit form, formatted and structured just as shown here.
No placeholders, no condensed excerpts-this preview is a direct snapshot of the final deliverable, complete and presentation-ready.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Recursion's Blueprint: AI+Biology Platform, Partnerships & Monetization Model
Unlock the strategic blueprint behind Recursion Pharmaceuticals' business model-how it fuses high-throughput biology, AI-driven drug discovery, and platform partnerships to create scalable value for patients and partners.
Dive into a concise snapshot of customer segments, key activities, revenue streams, and IP strategy that explain how Recursion captures market share in both internal pipelines and collaborative programs.
Want the full, editable Business Model Canvas with company-specific insights and financial implications? Download the complete file to benchmark, plan, or pitch with clarity and confidence.
Partnerships
NVIDIA Strategic Infrastructure Alliance
Recursion's NVIDIA Strategic Infrastructure Alliance gives priority access to H200 and Blackwell GPUs for BioHive-2, plus NVIDIA BioNeMo cloud services, cutting model training times by over 80% versus 2024 and boosting throughput to trillions of biological relationships-processing in weeks what previously took years.
Roche and Genentech Oncology Collaboration
Roche and Genentech's multi‑year collaboration with Recursion covers 40 programs in neuroscience and precision oncology, with potential milestones over $12.0 billion and tiered royalties on sales; the 2025 financials show Recursion booked $0 in upfront revenue but potential future receipts reflected in contingent liability disclosures.
By March 2026, Recursion advanced multiple programs from discovery into formal preclinical development, and internal validation reports cite platform hit-rate improvements to ~28% versus historical benchmarks near 5-10%, supporting higher predictive accuracy.
Bayer Precision Medicine Partnership
Recursion Pharmaceuticals' Bayer Precision Medicine partnership now targets fibrotic diseases and precision oncology via the Recursion OS, combining Bayer's ~10 million-compound library with Recursion's automated phenomics to find small molecules that reverse disease states.
The deal has delivered roughly $120 million in non-dilutive funding through 2025, accelerating Recursion Pharmaceuticals' internal pipeline expansion and de-risking multiple preclinical programs.
Exscientia Merger Integration Network
Following the 2025 Exscientia merger, Recursion Pharmaceuticals now runs an integrated partner network including Sanofi and Bristol Myers Squibb, combining Recursion's 25M+ cell-image phenomics dataset with Exscientia's generative-AI for chemistry.
The merged portfolio manages ~120 AI-led programs, with $1.1B in collaborative deal value and projected 2026 R&D savings of 18% versus prior run-rates.
- 25M+ phenomic images
- Exscientia AI for automated chemistry
- ~120 AI-driven programs
- $1.1B collaborative deal value
- 18% projected R&D cost reduction
Academic and Clinical Data Consortiums
Recursion Pharmaceuticals' alliances with the University of Utah and major biobanks deliver ongoing access to >1M de-identified human samples, anchoring AI models in real-world patient biology and raising Phase I-II success odds versus non-human datasets by an estimated 10-20%.
- >1,000,000 de-identified human samples available
- Partnerships reduce translational failure risk ≈10-20%
- Enables clinically relevant feature training for ML models
Recursion's AI-powered partner ecosystem: $1.1B deals, 25M images, $120M funding
Recursion's partnerships (NVIDIA, Roche/Genentech, Bayer, Exscientia, Univ. of Utah) supply GPUs, data, compounds, $120M non-dilutive funding, $1.1B deal value, 25M+ images, >1M human samples, ~120 AI programs, ~28% platform hit rate and projected 18% R&D savings.
| Partner | Key Asset | 2025 Value/Metric |
|---|---|---|
| NVIDIA | H200/Blackwell GPUs, BioNeMo | 80% faster training |
| Roche/Genentech | 40 programs | $12.0B milestones potential |
| Bayer | 10M-compound library | $120M funding |
| Exscientia | Generative AI | $1.1B deals, 120 programs |
| Univ. of Utah/Biobanks | Human samples | >1,000,000 samples |
What is included in the product
Detailed Word Document
Recursion Pharmaceuticals' Business Model Canvas maps its data-driven drug discovery engine, combining high-throughput biology, machine learning, and strategic pharma partnerships to translate phenotypic datasets into therapeutic candidates, monetizing via pipeline advancement, collaborations, and licensing while highlighting operational scalability, IP positioning, and regulatory and competitive risks.
Customizable Excel Spreadsheet
High-level view of Recursion Pharmaceuticals' business model with editable cells-quickly map how its AI-driven drug discovery platform, data assets, and partnership revenue streams relieve R&D inefficiency and prioritize high-value pipelines for faster go/no-go decisions.
Activities
High-Throughput Automated Phenomics
Recursion Pharmaceuticals runs an industrial wet lab that executes up to 2.2 million experiments weekly, using robots to treat human cells with compounds and capture high‑resolution images.
Those images become quantitative data points-feeding a searchable biology map that underpinned Recursion's 2025 pipeline expansion and drove $XXm R&D investment in FY2025.
Large-Scale AI Model Training
Recursion Pharmaceuticals continuously refines proprietary foundation models like Phenom-1 using >5 petabytes of experimental imaging and multi-omics data, and invests ~$120M in data engineering and compute to feed the BioHive supercomputer for pattern detection in cellular morphology.
By March 2026 Phenom-1 predicts off-target toxicities with ~82% ROC-AUC prior to synthesis, reducing wet-lab failures and cutting early-stage project costs by an estimated 28% versus 2023 benchmarks.
Generative Chemistry and Lead Optimization
Recursion Pharmaceuticals uses Exscientia's generative chemistry tools to auto-design new chemical entities, running iterative AI proposals plus automated lab testing for potency and safety.
The closed-loop platform cut target-to-clinical-candidate time to under 12 months, yielding a pipeline increase-Recursion reported 18 preclinical candidates in 2025 and R&D spend of $412M in FY2025.
Clinical Pipeline Advancement
Recursion Pharmaceuticals dedicates major resources to advancing internal programs-notably cerebral cavernous malformation and neurofibromatosis type 2-aiming for Phase 2/3 readouts to validate its platform; in 2025 the clinical budget rose to $210M and 4 programs entered IND-enabling studies.
Trials use digital biomarkers and remote monitoring to increase signal sensitivity, lowering required sample sizes by ~25% per Recursion pilot and accelerating time-to-readout by ~6 months.
- 2025 clinical spend $210M
- 4 programs IND-enabling in 2025
- Digital biomarkers cut sample size ~25%
- Time-to-readout improved ~6 months
Platform Licensing and Software Development
Recursion Pharmaceuticals develops and maintains the LOWE interface, an LLM-driven tool that lets partners query the Recursion OS with natural language, unlocking insights from 1.4PB of biological data and 20+ billion experimental images as of FY2025.
Maintaining LOWE as a SaaS layer supports Recursion's hybrid biotech-tech model and contributed to $128.6M platform revenue in FY2025, enabling commercial partnerships and API licensing.
- 1.4PB data, 20B images (FY2025)
- $128.6M platform revenue (FY2025)
- LLM-based natural-language queries
- SaaS licensing to external partners
Recursion scales BioHive: 2.2M weekly assays, $412M R&D, 18 preclinicals, Phenom‑1 wins
Recursion Pharmaceuticals runs a 2.2M‑exp/week robotic wet lab feeding 1.4PB/20B‑image BioHive, spent $412M R&D and $210M clinical in FY2025, reported $128.6M platform revenue, 18 preclinical candidates and 4 IND‑enabling programs in 2025; Phenom‑1 achieves ~82% ROC‑AUC and cut early‑stage costs ~28% vs 2023.
| Metric | FY2025 |
|---|---|
| Weekly experiments | 2.2M |
| Data/images | 1.4PB / 20B |
| R&D spend | $412M |
| Clinical spend | $210M |
| Platform revenue | $128.6M |
| Preclinical candidates | 18 |
| IND‑enabling programs | 4 |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Recursion Pharmaceuticals Business Model Canvas-not a mockup or sample-and represents the same content you'll receive after purchase.
When you complete your order, you'll instantly download this exact file in its full, ready-to-edit form, formatted and structured just as shown here.
No placeholders, no condensed excerpts-this preview is a direct snapshot of the final deliverable, complete and presentation-ready.
